On the back of SIGA Tech­nolo­gies' win with the FDA, the mon­key­pox virus sees the com­pa­ny spring­ing to fur­ther ac­tion

As the cas­es of mon­key­pox now sit at well over 100 world­wide and have spread to mul­ti­ple con­ti­nents, the or­ders for any type of vac­cine against mon­key­pox are see­ing na­tions and med­ical bod­ies look­ing to get their hands on any­thing and every­thing. And now SIGA Tech­nolo­gies seems to be get­ting in on the ac­tion.

Ac­cord­ing to Eu­ronews, SIGA Tech­nolo­gies, a phar­ma­ceu­ti­cal com­pa­ny that is fo­cused on pro­vid­ing med­ical coun­ter­mea­sures to bi­o­log­i­cal and chem­i­cal at­tacks, is now in talks with sev­er­al Eu­ro­pean au­thor­i­ties look­ing to stock­pile its an­tivi­ral that can counter mon­key­pox. The drug known as tecovir­i­mat or Tpoxx was ap­proved by the FDA in 2018 as a vac­cine for small­pox but was ap­proved by the Eu­ro­pean Med­i­cines Agency to al­so act against mon­key­pox, cow­pox and com­pli­ca­tions from im­mu­niza­tion with vac­cinia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER